Ignite Creation Date:
2025-12-24 @ 2:54 PM
Ignite Modification Date:
2025-12-24 @ 2:54 PM
Study NCT ID:
NCT04215159
Status:
UNKNOWN
Last Update Posted:
2020-01-02
First Post:
2019-09-24
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Trastuzumab Biosimilar (Samfenet®) Plus Treatment of Physician's Choice (TPC) in Patients With HER2-positive Solid Tumor
Sponsor:
Jin-Hee Ahn
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2019-12-30
Start Date Type:
ESTIMATED
Primary Completion Date:
2019-12-30
Primary Completion Date Type:
ESTIMATED
Completion Date:
2019-12-30
Completion Date Type:
ESTIMATED
First Submit Date:
2019-09-24
First Submit QC Date:
None
Study First Post Date:
2020-01-02
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2019-12-31
Last Update Post Date:
2020-01-02
Last Update Post Date Type:
ACTUAL